#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.
The Peter Attia Drive View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Richard Miller is a professor of pathology and the Director of the Center for Aging Research at the University of Michigan, as well as a previous guest on The Drive. In this episode, Rich provides an update on the exciting work of the Interventions Testing Program (ITP), an initiative designed to assess potential life-extending interventions in mice. Rich covers the notable successes like rapamycin, 17⍺-estradiol, and acarbose as well as notable failures like nicotinamide riboside, metformin, and resveratrol, providing valuable lessons about the intricacies of the aging process. Rich delves deep into aging biomarkers and aging rate indicators, unraveling cr
0
(-)
Rate this episode:
Episode mentions
You can listen to this podcast, but not everything mentioned in it has been defined yet. Upvote it if you want it to be added next - the most voted podcasts will be added as soon as possible
Transcript
This episode has not been transcribed yet. Upvote it if you want it to be added next - the most voted podcasts will be added as soon as possible.